calpain-inhibitor-iii and Leishmaniasis--Cutaneous

calpain-inhibitor-iii has been researched along with Leishmaniasis--Cutaneous* in 2 studies

Other Studies

2 other study(ies) available for calpain-inhibitor-iii and Leishmaniasis--Cutaneous

ArticleYear
The potent cell permeable calpain inhibitor MDL28170 affects the interaction of Leishmania amazonensis with macrophages and shows anti-amastigote activity.
    Parasitology international, 2017, Volume: 66, Issue:5

    Since the discovery of the28 first drugs used in leishmaniasis treatment up to now, the search for compounds with anti-Leishmania activity without toxic effects and able to overcome the emergency of resistant strains remains a major goal to combat this neglected disease. With this in mind, in the present work, we evaluated the effects of the calpain inhibitor MDL28170 on the interaction process of Leishmania amazonensis promastigote forms with murine peritoneal macrophages and on the intracellular amastigotes. Our results showed that the calpain inhibitor MDL28170 at 15 and 30μM significantly reduced the interaction process of promastigotes with macrophages by 16% and 41%, respectively. The inhibitor was also able to drastically reduce the number of infected macrophages in a time- and dose-dependent manner: after only 24h, MDL28170 was able to significantly diminish the infection rate, presenting an IC

    Topics: Animals; Antiprotozoal Agents; Cell Survival; Cysteine Proteinase Inhibitors; Dipeptides; Host-Parasite Interactions; Inhibitory Concentration 50; Leishmania mexicana; Leishmaniasis, Cutaneous; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Nitric Oxide; Tumor Necrosis Factor-alpha

2017
The calpain inhibitor MDL28170 induces the expression of apoptotic markers in Leishmania amazonensis promastigotes.
    PloS one, 2014, Volume: 9, Issue:1

    Human cutaneous leishmaniasis is caused by distinct species, including Leishmania amazonensis. Treatment of cutaneous leishmaniasis is far from satisfactory due to increases in drug resistance and relapses, and toxicity of compounds to the host. As a consequence for this situation, the development of new leishmanicidal drugs and the search of new targets in the parasite biology are important goals.. In this study, we investigated the mechanism of death pathway induced by the calpain inhibitor MDL28170 on Leishmania amazonensis promastigote forms. The combined use of different techniques was applied to contemplate this goal. MDL28170 treatment with IC50 (15 µM) and two times the IC50 doses induced loss of parasite viability, as verified by resazurin assay, as well as depolarization of the mitochondrial membrane, which was quantified by JC-1 staining. Scanning and transmission electron microscopic images revealed drastic alterations on the parasite morphology, some of them resembling apoptotic-like death, including cell shrinking, surface membrane blebs and altered chromatin condensation pattern. The lipid rearrangement of the plasma membrane was detected by Annexin-V labeling. The inhibitor also induced a significant increase in the proportion of cells in the sub-G0/G1 phase, as quantified by propidium iodide staining, as well as genomic DNA fragmentation, detected by TUNEL assay. In cells treated with MDL28170 at two times the IC50 dose, it was also possible to observe an oligonucleossomal DNA fragmentation by agarose gel electrophoresis.. The data presented in the current study suggest that MDL28170 induces apoptotic marker expression in promastigotes of L. amazonensis. Altogether, the results described in the present work not only provide a rationale for further exploration of the mechanism of action of calpain inhibitors against trypanosomatids, but may also widen the investigation of the potential clinical utility of calpain inhibitors in the chemotherapy of leishmaniases.

    Topics: Apoptosis; Cysteine Proteinase Inhibitors; Dipeptides; DNA Fragmentation; DNA, Protozoan; G1 Phase; Gene Expression Regulation; Humans; Leishmania; Leishmaniasis, Cutaneous; Membrane Potential, Mitochondrial; Protozoan Proteins; Resting Phase, Cell Cycle

2014